Chicago, IL (PRWEB) August 09, 2013
The prescription drug resource center DrugRisk.com is announcing updated information for patients taking the blood thinner Pradaxa. A federal court overseeing more than 1,000 lawsuits alleging the drug caused internal bleeding recently denied an attempt by the maker of the drug to dismiss a case*.
DrugRisk provides patients taking popular prescription drugs with the latest warnings, recalls, studies and legal news to improve safety and awareness. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.
Pradaxa is a blood thinner approved by the FDA in 2010 as a stroke preventative for patients with atrial fibrillation. Experts disagree, however, about its risks for internal bleeding. The FDA has advised Pradaxa is no more dangerous than traditional blood thinner warfarin**.
Others, like the Institute for Safe Medication Practices, have warned that patients may be nearly 5 times as likely to die from bleeding with Pradaxa than that from warfarin***. DrugRisk has also added a recent study from the Netherlands which suggests patients taking newer blood thinners like Pradaxa may be 55% more likely to suffer internal bleeding****.
So far, more than 1,133 patients have filed a Pradaxa lawsuit alleging internal bleeding, with cases now consolidated to a special federal court in Illinois. The case is formally known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
Now, DrugRisk has learned that Judge David Herndon, who is overseeing the cases, recently blocked attempts by drug maker Boehringer Ingelheim to dismiss a case in which a man alleges Pradaxa caused him internal bleeding injury*.
Anyone affected by internal bleeding after taking Pradaxa is encouraged to visit DrugRisk.com<
Copyright©2012 Vocus, Inc.
All rights reserved